VivoSeq
Oncology

Follicular Lymphoma (FL)

11

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Follicular Lymphoma (FL) is an emerging landscape with 11 programs across 7 companies. The most active players are Roche, Genmab, Regeneron. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

3 programs

Phase 3Genmab logo

Genmab

1 program

Phase 3Regeneron logo

Regeneron

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3A

Azurity Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 311

Odronextamab

Regeneron

Rituximab

Roche

Cyclophosphamide

Baxter Healthcare Corporation

Doxorubicin

Pfizer

Vincristine

Eli Lilly

Approved
No programs

Analysis

Modality Breakdown

64%

Small molecule

7 of 11 classified programs — the dominant modality here.

36%ALL OTHERSMonoclonal antibody436%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Active, not recruiting·Genmab logoGenmab·Phase 3·NCT05409066·549 enrolled
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Recruiting·Genmab logoGenmab·Phase 3·NCT06191744·1,095 enrolled
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Recruiting·Regeneron logoRegeneron·Phase 3·NCT06091254·822 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)